Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) on April 25 and set a price target of $30.00. The company’s shares closed last Thursday at $10.85, close to its 52-week low of $9.70.
According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -1.2% and a 40.2% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Jazz Pharmaceuticals, and Aerie Pharma.
Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $24.44, implying an 116.5% upside from current levels. In a report issued on April 28, RBC Capital also maintained a Buy rating on the stock with a $22.00 price target.
The company has a one-year high of $33.97 and a one-year low of $9.70. Currently, Aurinia Pharmaceuticals has an average volume of 2.81M.
Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AUPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Read More on AUPH:
- Analysts Are Bullish on Top Materials Stocks: Newcrest Mining Limited (NCMGF), Paladin Energy Ltd (PALAF)
- Wall Street Analysts Are Bullish on Top Services Picks
- Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), Clinuvel Pharmaceuticals Limited (CLVLF)
- Hiscox (HCXLF) Receives a Hold from Barclays
- Trainline (TNLIF) Receives a Sell from Barclays